Genetic engineering concept. Medical science. Scientific Laboratory.
image-

LineaRx signs agreement with TYME Technologies

Posted on

Applied DNA Sciences announced that LineaRx, the Company’s majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has signed a definitive agreement with Tyme Technologies, to supply the Company’s Vita-Assay™ invasive Circulating Tumor Cell (iCTC) capture assay and associated services for use in the pivotal stage of the TYME-88-PANC clinical trial for patients with third-line pancreatic […]

Read More email

image-

LineaRx Signs Agreement with TYME Technologies for Functional ICTC Assay Services in Pancreatic Cancer Trial

Posted on

STONY BROOK, N.Y., November 26, 2019 –  Applied DNA Sciences, Inc. (NASDAQ: APDN; the “Company” or “Applied DNA”) announced today that LineaRx, Inc., the Company’s majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has signed a definitive agreement with Tyme Technologies, Inc. to supply the Company’s Vita-Assay™ invasive Circulating Tumor Cell (iCTC) capture assay and associated services […]

Read More email

image-

Applied DNA Sciences Reports 14 Development Customers for its Linear DNA Manufacturing Platform

Posted on

STONY BROOK, N.Y., November 25, 2019 –  Applied DNA Sciences, Inc. (NASDAQ: APDN, Applied DNA, “the Company”) announced today that LineaRx, Inc., its majority-owned subsidiary focused on next-generation biotherapeutics and diagnostics, has grown its customer base to fourteen companies currently testing its linear DNA manufacturing platform for the development of nucleic acid-based therapies and diagnostics.  The Company […]

Read More email

image-

iCTC Platform Shows Superior Correlation over PSA as a Biomarker

Posted on

STONY BROOK, N.Y., October 1, 2019 – LineaRx, Inc., the majority-owned subsidiary of Applied DNA Sciences, Inc. (NASDAQ: APDN) focused on next-generation biotherapeutics, announced today that its invasive Circulating Tumor Cells (iCTCs) platform demonstrated superior correlation over Prostate Specific Antigen (PSA) in an ongoing Phase II trial in recurrent prostate cancer. Most notably, the concentration of rare iCTCs […]

Read More email

image-

For Applied DNA, New Blood — And A Shot In The Arm

Posted on

AUGUST 12, 2019 By GREGORY ZELLER // Just 11 months after spinning off from its parent company, a Stony Brook startup with expansion in its DNA has made its first corporate acquisition. LineaRX, a subsidiary of Applied DNA Sciences, has acquired the physical assets and intellectual property of Vitatex Inc., a private biotech with close ties to Stony […]

Read More email

image-

LineaRx Acquires Cancer Cell Analysis Firm Vitatex

Posted on

August 8, 2019 NEW YORK — LineaRx said today that it has acquired the assets and intellectual property of Vitatex, a developer of invasive circulating tumor cell (iCTC) analysis technologies. According to LineaRx — an Applied DNA Sciences subsidiary formed around technologies for DNA design, manufacture, and chemical modification by large scale PCR —  Vitatex’s technologies allows […]

Read More email

image-

LineaRx Acquires Assets and Intellectual Property of Vitatex

Posted on

STONY BROOK, NY. August 8, 2017 – LineaRx, Inc. (“LineaRx”), a wholly-owned subsidiary of Applied DNA Sciences, Inc. (“Applied DNA or the Company,” NASDAQ: APDN), announced today that it has acquired the physical assets and Intellectual Property (IP) of Vitatex Inc. (“Vitatex”), a private biotechnology company focused on advancing personalized medicine with an innovative solution […]

Read More email